Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.

Starting soon · Phase 1

Conditions studied: Erectile Dysfunction

In brief

The objective of this phase 1, open-label, single-center, two-way crossover trial is to evaluate the pharmacokinetics (PK), safety, and tolerability of 100 mg ASP-001 oral liquid suspension versus 100 mg Viagra (sildenafil citrate) tablets in fasted, healthy male volunteers

Key facts

Study ID

NCT06782659

Run by

Aspargo Labs, Inc

People needed

56

Starts

2025-01-01

Expected to finish

2025-03-01

Last updated by the study team

2025-01-20

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• The participant must be informed of the nature of the study and voluntarily agree to participate by signing an informed consent form prior to any study-specific procedures.
• Participants must be healthy male volunteers aged 18 to 55 years (inclusive) at the time of dosing.
• Participants must have a body mass index between 18.0 and 29.9 kg/m² (inclusive) and a body weight of 50 to 100 kg (inclusive).
• Participants must be judged by the Investigator or designee to be in good general health, as documented by medical history, physical examination, clinical laboratory tests, vital signs, and 12-lead electrocardiogram (ECG). Any deviations from normal ranges must be assessed and deemed not clinically significant by the Investigator or designee.
• Participants must have a creatinine clearance (CrCl) value greater than 80 mL/min, as calculated by the Cockcroft-Gault equation.
• Participants must agree to practice an acceptable method of contraception as outlined in the protocol.

You may not qualify if…

• Unwillingness or inability to follow the procedures specified by the protocol.
• Participant received any investigational drug/product within 30 days prior to the first dose.
• History of significant renal, hepatic, cardiovascular (including orthostatic hypotension), psychiatric, neoplastic, inflammatory, infectious, diabetes mellitus, or other disease which, in the opinion of the Investigator, represents a safety risk for taking part in the study.
• Presence of any clinically significant results from laboratory tests, vital signs assessments, and electrocardiograms, as judged by the Investigator and/or designee.
• Any degree of hepatic impairment based on liver function testing (abnormal ALT, AST, bilirubin, alkaline phosphatase, prothrombin time and international normalized ratio during screening).
• Demonstrates a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
• Reports a clinically significant illness during the 28 days prior to first dose (as determined by the Investigator and/or designee).
• Subjects with known hypersensitivity to sildenafil or any component in the study medication, such as peppermint oil.
• Reports a history of clinically significant allergies including food or drug allergies as judged by the Investigator.
• History of drug abuse within the previous year, or a positive drug screen (amphetamines, barbiturates, benzodiazepines, cannabinoids, Cocaine, Opiates, Phencyclidine, 3,4-methylenedioxymethamphetamine (MDMA)) at screening and/or Day -1.
• Regular alcohol consumption of >15 units per week, with one unit being equivalent to 330mL of beer or 125 mL of wine or 25 mL to 40 mL of ≥ 40% spirits, or a positive alcohol breathalyzer test at screening and/or Day -1.
• Reports use of CYP enzyme inhibitors within 14 days prior to Period 1 dosing.
• Reports use of CYP enzyme inducers or St. John's Wort within 28 days prior to Period 1 dosing.
• Use of prescription or non-prescription drugs, including individual vitamins, herbal and dietary supplements within seven days or five half-lives, whichever is longer, unless in the opinion of the Investigator and Sponsor's medical monitor the medication is not expected to interfere with the study procedures or compromise subject safety (occasional use of acetaminophen, naproxen, and ibuprofen are allowed).
• Blood donation or significant blood loss within 3 months before screening. All volunteers will be advised not to donate blood for 30 days after completing the study.
• Reports donating plasma (e.g., plasmapheresis) within 14 days prior to first dose. All volunteers will be advised not to donate plasma for 30 days after completing the study.
• Demonstrates, in the opinion of study staff, inadequate veins or veins unsuitable for repeated venipuncture (e.g., veins difficult to locate, access, or puncture; veins with a tendency to rupture during or after puncture).
• Reports difficulty fasting or consuming standardized meals.
• Subjects who have difficulty swallowing.
• Regular use of tobacco (>4 cigarettes per day) or nicotine-containing products within four weeks before screening, or urinary cotinine level indicative of active smoking at screening and/or Day -1
• Major surgery within three months or minor surgery within one month before screening as per the Principal Investigator (PI) judgment.
• If, in the opinion of the PI, the subject is not suitable for the study.
• Institutionalized volunteers.
• Reports use of any hormone replacement therapy within 6 months prior to first dose.
• Use of any products containing Seville oranges, grapefruit and pomelo within seven days prior to first dose and for the duration of the study.

Where it is running

• Evolution Research Group, Clinical Pharmacology of Miami (CPMI) — Miami, Florida, United States
• Evolution Research Group, Clinical Pharmacology of Miami (CPMI) — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.